Filing Details
- Accession Number:
- 0001562180-22-000159
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-04 21:05:30
- Reporting Period:
- 2022-01-01
- Accepted Time:
- 2022-01-04 21:05:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1590877 | Regenxbio Inc. | RGNX | Biological Products, (No Disgnostic Substances) (2836) | 471851754 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1700659 | Steve Pakola | C/O Regenxbio Inc. 9804 Medical Center Drive Rockville MD 20850 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2022-01-01 | 1,152 | $32.70 | 9,848 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2022-01-03 | 1,598 | $33.75 | 8,250 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-01-03 | 8,900 | $0.00 | 17,150 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2022-01-03 | 42,500 | $0.00 | 42,500 | $34.31 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 42,500 | 2032-01-03 | No | 4 | A | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades at prices ranging from $33.72 to $33.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer.
- 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer.
Billionaire Hedge Funds
